Meeting
2016 ASCO Annual Meeting
Dynamics of mutant BRAF V600E in free circulating DNA (fcDNA) of non-melanoma cancer patients (pts) in response to treatment with BRAF and MEK/EGFR inhibitors.
Authors
Morten Mau-Soerensen
Department of Oncology, Rigshospitalet, Copenhagen, Denmark
Morten Mau-Soerensen , Lise Barlebo Ahlborn , Lars Joenson , Olga Oestrup , Jane Preuss Hasselby , Eric Santoni-Rugiu , Finn Cilius Nielsen , Ulrik Niels Lassen , Christina Westmose Yde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Circulating Biomarkers
Clinical Trial Registration Number
NCT02290522
Citation
J Clin Oncol 34, 2016 (suppl; abstr 11531)
DOI
10.1200/JCO.2016.34.15_suppl.11531
Abstract #
11531
Poster Bd #
228
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
First Author: Johanna C. Bendell
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.
First Author: Yungchang Chen
Poster
2016 Gastrointestinal Cancers Symposium
Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.
First Author: Van Karlyle Morris II
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu